Datroway (Datopotamab Deruxtecan-Dlnk) for Lung Cancer

Overview
Datroway is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has an epidermal growth factor receptor (EGFR) mutation. It is specifically for people who have already been treated with both EGFR-targeted therapy and platinum-based chemotherapy. This approval was granted under the FDA’s accelerated approval pathway based on tumor response and how long the response lasts. Continued approval may depend on further clinical trial results. Datroway is also known by its drug name, datopotamab deruxtecan-dlnk.

Datroway is an antibody-drug conjugate. It combines a targeted antibody with a chemotherapy drug to deliver treatment directly to cancer cells. Scientists believe it works by binding to Trop-2 proteins on cancer cells and releasing a topoisomerase inhibitor that damages the cancer cell’s DNA, slowing or stopping its growth.

How do I take it?
Prescribing information states that Datroway is given as an intravenous (IV) infusion once every three weeks (21-day cycle). Each dose must be diluted and prepared by a healthcare provider. Before receiving the infusion, the recipient is premedicated to help prevent nausea, vomiting, and infusion reactions. Datroway should be administered exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Datroway include mouth sores (stomatitis), nausea, alopecia (hair loss), fatigue, anemia (low red blood cell count), low lymphocyte count, constipation, high calcium levels, increased liver enzymes, low white blood cell count, high lactate dehydrogenase, muscle and joint pain, decreased appetite, and skin rash.

Rare but serious side effects may include interstitial lung disease (a serious lung condition that causes scarring and breathing problems), severe eye problems such as dry eyes, keratitis (inflammation of the cornea), blepharitis (eyelid inflammation), and blurred vision. Other serious risks include oral mucositis (severe mouth inflammation), risk to an unborn baby, and possible effects on fertility.

For more information about this treatment, visit:

Datroway (Datopotamab Deruxtecan-Dlnk) for Injection, for Intravenous Use — Daiichi Sankyo